Crinetics Pharmaceuticals (CRNX) Interest & Investment Income (2017 - 2026)

Crinetics Pharmaceuticals' Interest & Investment Income history runs 10 years deep, the most recent figure standing at $12.7 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 14.63% year-over-year to $12.7 million in Q1 2026; TTM through Mar 2026 was $26.5 million, a 14.74% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 97.41% from the prior year.
• Interest & Investment Income improved to $12.7 million in Q1 2026 per CRNX's latest filing, from -$206000.0 in the prior quarter.
• Across five years, Interest & Investment Income topped out at $14.8 million in Q1 2025 and bottomed at -$6.0 million in Q4 2022.
• The 5-year median for Interest & Investment Income is $1.4 million (2023), against an average of $3.6 million.
• Across the five-year window, Interest & Investment Income sank 7552.5% in 2022 and jumped 4057.35% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at -$6.0 million in 2022, then surged by 69.71% to -$1.8 million in 2023, then jumped by 895.57% to $14.4 million in 2024, then sank by 101.43% to -$206000.0 in 2025, then surged by 6247.57% to $12.7 million in 2026.
• Per Business Quant, the three latest CRNX Interest & Investment Income figures stand at $12.7 million (Q1 2026), -$206000.0 (Q4 2025), and $594000.0 (Q3 2025).